- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.12. | Regeneron and Tessera join forces to forge in vivo AATD gene therapy | ||
| 01.12. | "Sharp" funding cuts disrupt PrEP access to millions of HIV patients | ||
| 01.12. | Eisai seeks PMDA approval for subcutaneous Leqembi in Japan | ||
| 01.12. | US FDA approves Lupin's Armlupeg injection | ||
| 28.11. | WHO warns of immunisation strategy gaps amid measles outbreaks | ||
| 28.11. | Celltrion secures Health Canada go-ahead for Eylea biosimilar | ||
| 28.11. | Over half of European HIV patients diagnosed late, ECDC report finds | ||
| 28.11. | IASO Bio gains Hong Kong approval for Fucaso application | ||
| 27.11. | Valneva trims R&D footprint by shutting French facility | ||
| 27.11. | SK bolsters oncology pipeline in radiopharmaceutical licensing deal | ||
| 27.11. | BeOne's sonrotoclax gains priority FDA review for mantle cell lymphoma | ||
| 27.11. | Corstasis Therapeutics partners CVL for Enbumyst integration | ||
| 26.11. | Reeves' Autumn Budget targets community health centres and NHS tech outlay | ||
| 26.11. | Dupixent gains chronic spontaneous urticaria indication in Europe | ||
| 26.11. | Questions on how new IRA drug prices will affect MFN agreements | ||
| 26.11. | Novartis axes 550 jobs at Swiss manufacturing site | ||
| 26.11. | UNICEF and Gavi to widen affordable malaria vaccine access | ||
| 26.11. | FDA grants accelerated approval for Otsuka's IgAN therapy | ||
| 25.11. | Gilead snaps up Sprint's TREX1 immunotherapy programme for $400m | ||
| 25.11. | UK-developed leukaemia cell therapy to be offered on NHS | ||
| 25.11. | Made Scientific and Cellergy partner to advance CLG-001 | ||
| 25.11. | Novartis secures approval from FDA for Itvisma to treat SMA | ||
| 24.11. | GLP-1RA Alzheimer's hopes dashed after Novo Nordisk's semaglutide miss | ||
| 24.11. | Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club | ||
| 24.11. | Navigating the FDA's import operations for pharmaceuticals and biologics |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .